Table 1.
Baseline characteristics of STB patients with and without SCI in training set.
| Characteristics | No. (%) | p | ||
|---|---|---|---|---|
| Total | SCI (n = 141) | No-SCI (n = 105) | ||
| Age, years, median (IQR) | 54 (37–66) | 57 (41–67) | 48 (34–61) | 0.0003 |
| BMI, Mean ± SD | 20.9 ± 3.09 | 20.85 ± 2.85 | 20.89 ± 3.39 | 0.695 |
| Sex, n (%) | 0.079 | |||
| Male | 147 (59.8%) | 83 (33.7%) | 64 (26.1%) | |
| Female | 99 (40.2%) | 58 (23.6%) | 41 (16.6%) | |
| Diabetes, n (%) | 0.413 | |||
| Yes | 47 (19.1%) | 24 (9.8%) | 23 (9.3%) | |
| No | 199 (80.9%) | 117 (47.6%) | 82 (33.3%) | |
| Hypertension, n (%) | 0.0006 | |||
| Yes | 84 (34.1%) | 61 (24.8%) | 23 (9.3%) | |
| No | 162 (65.9%) | 80 (32.5%) | 82 (33.4%) | |
| CRP, median (IQR) | 14.3 (5.96–39.3) | 21.9 (7.43–52.2) | 10.8 (5.3–29.87) | 0.002 |
| WBC*10^9/L, median (IQR) | 7.08 (5.8–8.34) | 7.2 (6.04–8.66) | 6.9 (5.56–7.96) | 0.06 |
| NEU*10^9/L, median (IQR) | 4.53 (3.53–5.77) | 4.73 (3.81–6.07) | 4.08 (3.19–5.32) | 0.0002 |
| LYM*10^9/L, median (IQR) | 1.46 (1.09–1.79) | 1.38 (1.03–1.66) | 1.62 (1.24–1.91) | 0.0006 |
| MONO*10^9/L, median (IQR) | 0.61 (0.48–0.77) | 0.63 (0.52–0.81) | 0.58 (0.44–0.69) | 0.0009 |
| HGB g/L, median (IQR) | 123 (111–133) | 117 (106–131) | 126 (117–135) | 0.0007 |
| PLT *10^9/L, median (IQR) | 291 (247–351) | 310 (261–371) | 269 (237.6–309) | 0.0003 |
| ESR, median (IQR) | 40 (23.2–60) | 44 (30–67) | 34 (17–55) | 0.0004 |
| ALB g/L, median (IQR) | 38.6 (35.2–41.4) | 37.7 (33.3–39.9) | 39.3 (37.2–42) | 0.0005 |
| TP g/L, median (IQR) | 71.3 (67–74.9) | 71.3 (66.6–75.9) | 71.3 (67.6–74) | 0.919 |
| AST u/L, median (IQR) | 20 (17–26) | 20 (17–26) | 20 (17–27) | 0.715 |
| ALT u /L, median (IQR) | 16 (12–23) | 16 (12–22) | 17 (12–24) | 0.482 |
| Ure u/L, median (IQR) | 4.26 (3.35–5.21) | 4.32 (3.36–5.44) | 4.23 (3.34–5.13) | 0.554 |
| Scr u/L, median (IQR) | 67 (56–77.8) | 67 (55–77) | 67 (57–79) | 0.858 |
| UA u/L, Mean ± SD | 401 ± 166 | 398.16 ± 173.04 | 404.47 ± 157.01 | 0.586 |